Spotlight
Twitter feed
ICYMI: Rick Pazdur leads a discussion of the development and FDA review process for osimertinib—a treatment for NSCLC—in the current edition of Project Livin’ Label, an educational initiative between @FDAOncology and the AACR. CME credit available:
https://t.co/6ff3Plw7A9
ICYMI: March is #ColorectalCancerAwarenessMonth. Learn about efforts to increase colorectal cancer screening in underserved populations on the #AACRBlog:
https://t.co/xd8aDEnjJs
Abstract Deadline: March 15
Early Registration: March 31
The 16th International Conference on Malignant Lymphoma will be held in virtual format June 18-22, 2021. Submit an abstract and register now:
https://t.co/o1cEIxoFub
#16ICML @icmlugano
Everyone has something to teach: 6 tips from @inas_md on how oncology fellows can be teachers during their daily work even as they continue their own training #ASCOconnection
Fellows as Teachers: Paying It Forward
Our oncology training is shaped by those who devote their time to helping us turn our weaknesses into strengths, and all of us have a role to play as ...
fal.cn
Deadline: 11:59 PM ET, March 15
AACR Members: Voting is currently open for the following AACR offices:
—President-Elect
—Board of Directors (5 seats)
—Nominating Committee (4 seats)
Read the candidates' vision statements and cast your votes today:
https://t.co/mgSH0RBE8W
#AACRFellows Tony Hunter @salkinstitute, William @Kaelin_Lab, Olufunmilayo Olopade @UCCancerCenter, and Dennis Slamon @dgsomucla will discuss "Cancer Biology and the Changing Therapeutic Landscape" in a plenary at the #AACR21 Annual Meeting, Apr 10-15:
https://t.co/p4pmT4QfMe
#ASCODailyNews Podcast: @LaurenByersMD of @MDAndersonNews highlights a transformative new framework to classify #SCLC into 4 subtypes based on gene expression, paving the way for #PrecisionMedicine
ASCO Daily News: Accelerating Progress in Small Cell Lung Cancer
Dr. Lauren Byers, associate professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, highlights a ne...
fal.cn
New study in Journal of Clinical Oncology (@ASCO_pubs) led by Joyce Liu, MD, MPH shows new targeted agent achieved impressive response rate in trial with patients with uterine serous carcinoma
https://t.co/MSjKdySh17
#ClinicalResearchers are invited to apply for the one-year, $100,000 AACR Clinical Oncology Research (CORE) Training Fellowships. The program provides selected fellows with a unique training opportunity in drug development. Learn more:
https://t.co/2h8fNlHqJ7
Mechanisms, Impact, and Exploitation of Cancer Chromosomal Instability:
David Pellman, @Samuel_Bakhoum, @SPJacksonGroup, and @KarleneCimprich will address this topic in a Discovery Science Plenary Session at #AACR21. Learn more:
https://t.co/o0xEhDERQ8
Recent publications
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Front Oncol.
EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody drug conjugate HER3-DXd. Cancer Res.
Announcements
Donor highlight
Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.
